Interventional Cardiology, University of California, San Diego, San Diego, California.
Medicine, Interventional Cardiology, University of California, San Diego, VA San Diego Healthcare System, San Diego, California.
Catheter Cardiovasc Interv. 2019 Mar 1;93(4):613-617. doi: 10.1002/ccd.27867. Epub 2018 Nov 19.
To assess the long-term safety and efficacy of robotic percutaneous coronary revascularization for use in complex coronary lesions.
Robotically assisted percutaneous coronary intervention (PCI) is safe and feasible in simple coronary lesions and has excellent short-term procedural and clinical outcomes for complex lesions; however, long-term safety and efficacy outcomes are unknown.
A total of 103 consecutive patients underwent a total of 108 robotic (R)-PCI procedures (age 68.1; 78.3% male) over 18 months, and 210 patients underwent a total of 226 manual (M)-PCI procedures (age 67.5; 78.1% male) during the same period. Patients were subsequently followed and both 6-month and 12-month major adverse cardiovascular events (MACE), comprised of any death, stroke, myocardial infarction, or target vessel revascularization, are reported and compared.
There was no difference between the two groups with regard to overall MACE at 6 months (R-PCI 5.8% vs. M-PCI 3.3%, P = 0.51) or at 12 months (R-PCI 7.8% vs. M-PCI 8.1%, P = 0.92). There was no difference between the individual components of the primary combined endpoint at either time point. No access site complications occurred in either cohort that met BARC III or higher criteria.
At the 6- and 12-month time points following R-PCI, no difference in clinical outcomes or safety measures was observed as compared to M-PCI.
评估机器人经皮冠状动脉血运重建术治疗复杂冠状动脉病变的长期安全性和有效性。
机器人辅助经皮冠状动脉介入治疗(PCI)在简单的冠状动脉病变中是安全且可行的,对于复杂病变具有出色的短期手术和临床结果;然而,长期安全性和疗效结果尚不清楚。
在 18 个月内,共有 103 例连续患者接受了总共 108 例机器人(R)-PCI 手术(年龄 68.1;78.3%为男性),同期共有 210 例患者接受了总共 226 例手动(M)-PCI 手术(年龄 67.5;78.1%为男性)。随后对患者进行随访,并报告和比较了 6 个月和 12 个月时的主要不良心血管事件(MACE),包括任何死亡、中风、心肌梗死或靶血管血运重建。
在 6 个月(R-PCI 5.8%比 M-PCI 3.3%,P=0.51)或 12 个月(R-PCI 7.8%比 M-PCI 8.1%,P=0.92)时,两组间总体 MACE 无差异。在两个时间点,主要复合终点的各个组成部分均无差异。两个队列均未发生符合 BARC III 或更高标准的任何血管入路并发症。
与 M-PCI 相比,在 R-PCI 后 6 个月和 12 个月时,临床结局或安全性措施没有差异。